Lievense L - Search Results

1

Malignant pleural mesothelioma in US automotive mechanics: reported vs expected number of cases from 1975 to 2007.

Finley BL, Pierce JS, Paustenbach DJ, Scott LL, Lievense L, Scott PK, Galbraith DA. Finley BL, et al. Among authors: lievense l. Regul Toxicol Pharmacol. 2012 Oct;64(1):104-16. doi: 10.1016/j.yrtph.2012.05.015. Epub 2012 Jun 2. Regul Toxicol Pharmacol. 2012. PMID: 22668748 Review.

2

The role of genotoxicity in asbestos-induced mesothelioma: an explanation for the differences in carcinogenic potential among fiber types.

Barlow CA, Lievense L, Gross S, Ronk CJ, Paustenbach DJ. Barlow CA, et al. Among authors: lievense l. Inhal Toxicol. 2013 Aug;25(9):553-67. doi: 10.3109/08958378.2013.807321. Inhal Toxicol. 2013. PMID: 23905972 Review.

3

Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects.

Lievense LA, Heukels P, van Walree NC, van der Leest CH. Lievense LA, et al. JTO Clin Res Rep. 2022 Nov 25;4(1):100441. doi: 10.1016/j.jtocrr.2022.100441. eCollection 2023 Jan. JTO Clin Res Rep. 2022. PMID: 36578272 Free PMC article.

4

Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.

Dammeijer F, De Gooijer CJ, van Gulijk M, Lukkes M, Klaase L, Lievense LA, Waasdorp C, Jebbink M, Bootsma GP, Stigt JA, Biesma B, Kaijen-Lambers MEH, Mankor J, Vroman H, Cornelissen R, Baas P, Van der Noort V, Burgers JA, Aerts JG. Dammeijer F, et al. Among authors: lievense la. EBioMedicine. 2021 Feb;64:103160. doi: 10.1016/j.ebiom.2020.103160. Epub 2021 Jan 27. EBioMedicine. 2021. PMID: 33516644 Free PMC article.

5

Depletion of Tumor-Associated Macrophages with a CSF-1R Kinase Inhibitor Enhances Antitumor Immunity and Survival Induced by DC Immunotherapy.

Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG. Dammeijer F, et al. Among authors: lievense la. Cancer Immunol Res. 2017 Jul;5(7):535-546. doi: 10.1158/2326-6066.CIR-16-0309. Epub 2017 May 23. Cancer Immunol Res. 2017. PMID: 28536100

6

Checkpoint Blockade in Lung Cancer and Mesothelioma.

Lievense LA, Sterman DH, Cornelissen R, Aerts JG. Lievense LA, et al. Am J Respir Crit Care Med. 2017 Aug 1;196(3):274-282. doi: 10.1164/rccm.201608-1755CI. Am J Respir Crit Care Med. 2017. PMID: 28252315 Review.

7

Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Dammeijer F, Lievense LA, Veerman GD, Hoogsteden HC, Hegmans JP, Arends LR, Aerts JG. Dammeijer F, et al. Among authors: lievense la. J Clin Oncol. 2016 Sep 10;34(26):3204-12. doi: 10.1200/JCO.2015.66.3955. Epub 2016 Jul 18. J Clin Oncol. 2016. PMID: 27432922 Review.

8

Pleural Effusion of Patients with Malignant Mesothelioma Induces Macrophage-Mediated T Cell Suppression.

Lievense LA, Cornelissen R, Bezemer K, Kaijen-Lambers ME, Hegmans JP, Aerts JG. Lievense LA, et al. J Thorac Oncol. 2016 Oct;11(10):1755-64. doi: 10.1016/j.jtho.2016.06.021. Epub 2016 Jul 12. J Thorac Oncol. 2016. PMID: 27418106 Free article.

9

Precision immunotherapy; dynamics in the cellular profile of pleural effusions in malignant mesothelioma patients.

Lievense LA, Bezemer K, Cornelissen R, Kaijen-Lambers ME, Hegmans JP, Aerts JG. Lievense LA, et al. Lung Cancer. 2017 May;107:36-40. doi: 10.1016/j.lungcan.2016.04.015. Epub 2016 Apr 27. Lung Cancer. 2017. PMID: 27168021

10

Immune Therapy.

Lievense L, Aerts J, Hegmans J. Lievense L, et al. Adv Exp Med Biol. 2016;893:59-90. doi: 10.1007/978-3-319-24223-1_4. Adv Exp Med Biol. 2016. PMID: 26667339 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page